Leukemia treatment cost in the Republic of Korea runs from $19,200 to $41,000 for chemotherapy, while essential diagnostics like a complete blood count range from $100 to $100. Total expenses depend on the leukemia subtype, hospital tier, and necessary hospital stay duration. Patients typically save 40% to 60% compared to the US. Top cities for specialized hematology-oncology care include Seoul and Seongnam.
Typical Leukemia Treatment Costs in Republic of Korea
Bookimed Expert Insight: Patients seeking high-precision care benefit from digitalized facilities like Seoul National University Hospital. This center is preferred by South Korean presidents and reports the country's highest cancer treatment statistics. For those prioritizing safety and error prevention, Seoul National University Bundang Hospital (SNUBH) uses the BESTcare system. This digital infrastructure is ideal for complex drug administration. Samsung Medical Center provides a comprehensive cancer center with presidential-level service standards. It is best suited for international patients requiring advanced technologies like Novalis or IGRT. Large multidisciplinary hubs like Asan Medical Center offer high success rates for intensive procedures. Asan manages nearly 200,000 patients annually and provides specialized expertise for diverse medical tourists.
| Republic of Korea | Turkey | Austria | |
| Chemotherapy for breast cancer | from $19,200 | from $1,200 | from $15,000 |
| CAR T-cell therapy | from $385,000 | from $150,000 | from $350,000 |
| Leukemia chemotherapy | from $22,000 | from $8,000 | from $15,000 |
| Therapeutic Apheresis | - | from $1,350 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Leukemia treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Leukemia treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Leukemia treatment journey.
The doctor is the Director of the Yonsei Cancer Center at Yonsei University Health System in Seoul, South Korea. Specializing in the treatment of advanced gastric cancer, the doctor has extensive expertise in surgery, oncology, and gastroenterology.
The doctor has held prestigious positions such as President of the Korean Gastric Cancer Association and the International Gastric Cancer Association, and Chairman of the Board of the Korean Cancer Association and the Korean Surgical Society.
Recognized as an outstanding surgeon in gastric cancer surgery, the doctor has received numerous accolades, including the Cancer Academic Award and the Yuhan Academic Award.
The doctor is a pediatrician with a specialization in bone marrow transplantation and brain tumor treatment. Graduating with a Bachelor of Medicine, a Master's degree, and a PhD from Seoul National University, the doctor has extensive experience in both clinical practice and research.
Professional experience includes serving as a pediatrician at Samsung Medical Center, an Assistant Professor in the Department of Pediatrics at Samsung Clinic, and a researcher at the Oncology Center of Indiana University School of Medicine. The doctor has held leadership roles such as Head of the Children's Oncology Department at Samsung Hospital and currently serves as Head of the Department of Pediatrics at Samsung Clinic.
The doctor is a highly experienced Hematologist-Oncologist with over 26 years of expertise in the field. Specializing in the treatment of colon cancer, hematological oncology, myelomas, and lymphoma, the doctor is proficient in advanced procedures such as Bone Marrow Transplantation, including Alternate Donor and Mismatched Transplants.
With a strong academic background, the doctor holds an M.D. from Yonsei University College of Medicine and a Ph.D. from Sungkyunkwan University College of Medicine. The doctor is also a member of multiple professional societies and has contributed to the field through numerous paper publications.
The doctor is an expert in oncoplastic surgery and breast cancer, with extensive experience from prestigious institutions. The doctor holds an M.D. degree from Seoul National University College of Medicine and an M.S. degree in Surgery from the same institution. Additionally, the doctor earned a B.S. in biological sciences from the Korea Advanced Institute of Science and Technology (KAIST) and a Ph.D. in Surgery from Seoul National University Graduate School.
Written by Anna Leonova
Samsung Medical Center, Seoul National University Hospital, and Asan Medical Center lead South Korea in leukemia treatment. These JCI-accredited facilities specialize in advanced cell therapies and hematopoietic stem cell transplants. They consistently rank among the top global oncology centers for hematologic malignancy outcomes.
Bookimed Expert Insight: Patient volume often signals where practitioners see the most complex cases. Severance Hospital treats 4,000,000 patients annually and manages 3,700 beds. This high turnover suggests local surgeons maintain peak proficiency in performing frequent, high-stakes leukemia procedures.
Patient Consensus: Patients emphasize finding hospitals with English-speaking hematologists and JCI status. They note that leukemia care often requires months-long stays and careful budget planning for translation.
Advanced cellular therapies like CAR T-cell are available for leukemia patients in South Korea. Facilities like Samsung Medical Center and Severance Hospital utilize these treatments. Kymriah is currently approved for relapsed B-cell acute lymphoblastic leukemia. Specialist centers in Seoul use advanced Good Manufacturing Practice facilities.
Bookimed Expert Insight: Samsung Medical Center serves over 2,000,000 patients annually and maintains presidential health standards. This massive volume allows their Comprehensive Cancer Center to integrate technologies like Novalis into multi-modal leukemia protocols. This infrastructure is vital because CAR T-cell therapy requires highly specialized cell processing centers often only found in such large academic institutions.
Patient Consensus: Patients note that reaching these high-volume centers in Seoul provides peace of mind. They appreciate the clear, multidisciplinary approach where hematologists and cell specialists work together throughout the process.
International leukemia patients in Republic of Korea receive support through specialized centers accredited by KOIHA and JCI. Services include English-speaking coordinators, visa assistance, and digital health systems for error-free care. Major Seoul facilities provide medical interpreters to ensure clear instructions for complex protocols like CAR T-cell therapy.
Bookimed Expert Insight: High-volume centers like Severance and Samsung Medical Center handle millions of patients annually. Data shows that hospitals with GHA accreditation, such as SNUBH, offer superior logistics for international travelers. Patients should prioritize facilities that provide digital health tracking to ensure seamless post-treatment follow-ups.
Patient Consensus: Patients note that while hospitals provide coordinators, it is helpful to use apps like Papago for daily communication. Many recommend organizing long-term housing early, as leukemia therapy often requires several months near the clinic.
Foreign patients undergoing medical stem cell transplants for leukemia typically stay in South Korea for 1 to 3 months. Initial hospitalization for cell engraftment lasts 3 to 5 weeks. Patients must remain nearby for another 1 to 2 months for monitoring at specialized centers.
Bookimed Expert Insight: Samsung Medical Center serves over 2,000,000 patients annually and maintains presidential standards. This high volume allows for specialized monitoring infrastructure. Patients at such large centers often benefit from integrated diagnostic suites including cytogenetic studies. High patient capacity suggests refined protocols for managing the long recovery journey.
Patient Consensus: Patients note that the language barrier is manageable through clinic coordinators. They also emphasize that staying in Seoul after discharge is necessary for frequent blood tests.
South Korean hematologists use bone marrow aspiration, high-sensitivity flow cytometry, and next-generation sequencing (NGS) to guide leukemia therapy. These tests identify specific mutations like FLT3 or BCR-ABL1. Results dictate the use of targeted drugs, immunotherapy, or CAR T-cell therapy protocols.
Bookimed Expert Insight: The depth of diagnostic infrastructure in Seoul is exceptional, shown by clinics like Asan Medical Center and Severance Hospital managing millions of patients. These high-volume centers integrate the BESTcare digital system or presidential-grade equipment to prevent errors in fast-paced NGS reporting. Patients benefit because these institutions handle the highest cancer volumes, ensuring molecular results are interpreted with massive comparative data sets.
Patient Consensus: Patients emphasize requesting full genetic panels immediately at diagnosis to avoid missing targeted treatment windows. They also recommend obtaining raw reports to ensure all mutations are cross-checked against global databases.
Haploidentical transplants are widely available as a standard option in South Korea for patients lacking full-matched donors. This method uses a 50% genetic match from parents, children, or half-matched siblings. Specialized centers in Seoul report survival rates comparable to fully matched transplants.
Bookimed Expert Insight: South Korea has transitioned into a global leader for mismatched transplants. Data shows Asan Medical Center reports a 90% success rate for organ transplants. This expertise extends to hematology, where specialized protocols allow for faster engraftment. Patients should note that Samsung Medical Center and Severance Hospital often manage high international volumes. These centers offer streamlined donor testing that is significantly faster than European or American registries.
Patient Consensus: Patients mention that finding a half-match from a biological child is a viable and successful route. Many emphasize the importance of starting testing early to speed up the process.